DEXCOM INC
For the period ended Sep 30, 2025. Filed Oct 30, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 30, 2025
DXCM$79.92-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows (unaudited) for the and
DexCom, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| (In millions) | 2025 | 2024 |
| Operating activities | ||
| Net income | $569.0 | $424.5 |
| Adjustments to reconcile net income to cash provided by operating activities: | ||
| Depreciation and amortization | 186.6 | 159.9 |
| Share-based compensation | 124.6 | 127.1 |
| Non-cash interest expense | 5.6 | 5.6 |
| Deferred income taxes | 103.3 | (68.1) |
| Net (gains) losses on equity investments | (78.1) | 1.4 |
| Other non-cash income and expenses | (18.7) | (64.7) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (95.7) | (27.6) |
| Inventory | (45.9) | (20.3) |
| Prepaid and other assets | (7.9) | (13.8) |
| Operating lease right-of-use assets and liabilities, net | (4.5) | (3.0) |
| Accounts payable and accrued liabilities | 357.1 | 231.7 |
| Accrued payroll and related expenses | 56.6 | (64.3) |
| Deferred revenue and other liabilities | (5.3) | (0.3) |
| Net cash provided by operating activities | 1,146.7 | 688.1 |
| Investing activities | ||
| Purchases of marketable securities | (1,246.6) | (2,083.5) |
| Proceeds from sale and maturity of marketable securities | 1,755.1 | 2,419.2 |
| Purchases of property and equipment | (261.6) | (234.2) |
| Purchases of non-marketable equity securities | (18.0) | (6.2) |
| Other investing activities | 0.5 | 0.9 |
| Net cash provided by investing activities | 229.4 | 96.2 |
| Financing activities | ||
| Net proceeds from issuance of common stock | 28.1 | 28.2 |
| Purchases of treasury stock | (187.2) | (750.0) |
| Other financing activities | (5.1) | (11.4) |
| Net cash used in financing activities | (164.2) | (733.2) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 17.7 | 3.8 |
| Increase in cash, cash equivalents and restricted cash | 1,229.6 | 54.9 |
| Cash, cash equivalents and restricted cash, beginning of period | 607.3 | 567.5 |
| Cash, cash equivalents and restricted cash, end of period | $1,836.9 | $622.4 |
| Reconciliation of cash, cash equivalents and restricted cash, end of period: | ||
| Cash and cash equivalents | $1,835.7 | $621.2 |
| Restricted cash | 1.2 | 1.2 |
| Total cash, cash equivalents and restricted cash | $1,836.9 | $622.4 |
| Supplemental disclosure of non-cash investing and financing transactions: | ||
| Acquisition of property and equipment included in accounts payable and accrued liabilities | $46.4 | $77.6 |
| Right-of-use assets obtained in exchange for operating lease liabilities | $2.7 | $8.2 |
| Right-of-use assets obtained in exchange for finance lease liabilities | $1.4 | $11.8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.